CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today ...
– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full ...
Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of the TNG462 phase 1/2 clinical trial, the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results